USPTO Examiner COLEMAN CHARLES P - Art Unit 3683

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18663586Dynamically Controlled Treatment Protocols for Autonomous Treatment SystemsMay 2024March 2026Allow2210NoNo
18661355SYSTEMS AND METHODS FOR SELECTING AN INTERVENTION BASED ON EFFECTIVE AGEMay 2024December 2025Allow1900NoNo
18625510METHODS AND SYSTEMS FOR INFORMING PRODUCT DECISIONSApril 2024January 2026Abandon2210NoNo
18609451CARE PLAN ADMINISTRATION: PATIENT FEEDBACKMarch 2024April 2025Allow1200YesNo
18434170DEVICES, SYSTEMS, AND METHODS FOR ADHERENCE MONITORING AND PATIENT INTERACTIONFebruary 2024August 2025Abandon1810NoNo
18503014Method for Extracting Event Information from Calendar RepresentationsNovember 2023November 2025Abandon2410NoNo
18491759SimPillRxOctober 2023November 2025Abandon2510NoNo
18489412Disease-Specific Semantic Model Instance Generation and MaintenanceOctober 2023September 2025Abandon2330YesNo
18484083SYSTEMS AND METHODS FOR MEDICATION ADHERENCEOctober 2023January 2025Abandon1510NoNo
18372362APPARATUS AND METHOD FOR DETERMINING RARITY OF BIOMETRIC INFORMATION SIGNALSeptember 2023December 2025Abandon2710NoNo
18281192INFORMATION PROVIDING APPARATUS, INFORMATION PROCESSING METHOD, AND RECORDING MEDIUMSeptember 2023November 2025Abandon2620NoNo
18232231DETERMINING LIKELY RESPONSE TO ANTI-INFLAMMATORY AND PRO-RESOLVING THERAPIES FOR CARDIOVASCULAR DISEASE NON-INVASIVELYAugust 2023May 2024Allow1000NoNo
18232138DETERMINING LIKELY RESPONSE TO GLYCEMIC TREATMENT FOR CARDIOVASCULAR DISEASE NON-INVASIVELYAugust 2023May 2024Allow1000NoNo
18327863NIGHT LIGHT WITH EMBEDDED CELLULAR MODEMJune 2023June 2025Abandon2520NoNo
18321651CAP FOR OPTICAL ILLUMINATION ON A CONTAINERMay 2023December 2024Allow1920YesYes
18199002SYSTEMS AND METHODS FOR NODE GRAPH STORAGE FOR STORING PATIENT DATA ACROSS CLINICSMay 2023September 2024Allow1620YesNo
18132510SYSTEM FOR ADMINISTERING A MEDICAMENTApril 2023October 2024Allow1810NoNo
18188628SYSTEMS AND METHODS FOR MANAGING REGIMEN ADHERENCEMarch 2023January 2025Abandon2220YesNo
18177103DENTAL SCANNING SYSTEMSMarch 2023January 2026Abandon3540YesNo
18155724System and Method for Screening Potential Test Subjects for Participation in Recent TrialsJanuary 2023September 2024Allow2020NoNo
18097086ELECTRONIC INTERFACE FOR HEALTHCARE RESOURCE SCHEDULINGJanuary 2023September 2024Allow2030YesNo
18047518REMOTE DIAGNOSTIC TESTING SYSTEMS AND METHODSOctober 2022September 2025Abandon3510NoNo
17965818METHOD FOR DISEASE RISK ASSESSMENTOctober 2022June 2025Abandon3210NoNo
17962246ADAPTIVE SPECIMEN COLLECTION ORDER PROCESSINGOctober 2022June 2025Abandon3310NoNo
17786878METHODS AND SYSTEMS FOR DETERMINING OPTIMAL DECISION TIME RELATED TO EMBRYONIC IMPLANTATIONJune 2022January 2026Allow4320YesNo
17478847ELECTRICAL BICYCLE ("E-BIKE") DETECTOR FOR ENERGY EXPENDITURE ESTIMATIONSeptember 2021July 2025Abandon4630YesNo
17397836Method for providing wearable device-collected physiological information to relevant service providersAugust 2021November 2024Abandon4020NoNo
17180292CONNECTED FACILITY SYSTEMSFebruary 2021March 2026Abandon6040NoNo
17170030UPDATING A PHARMACEUTICAL CONTENT ITEMFebruary 2021November 2025Abandon5840YesNo
17143083GENERATING EMBEDDINGS OF MEDICAL ENCOUNTER FEATURES USING SELF-ATTENTION NEURAL NETWORKSJanuary 2021April 2025Abandon5140NoNo
17142791SYSTEMS AND METHODS FOR AUTOMATED PROCESSING OF MEDICAL PRESCRIPTIONSJanuary 2021February 2026Abandon6040YesNo
17127843ESTIMATING IMPACT OF PROPERTY ON INDIVIDUAL HEALTH -- COGNITIVE CALCULATORDecember 2020December 2024Allow4820YesNo
17114262SYSTEMS AND METHODS FOR AUTOMATED MEDICAL DIAGNOSTICSDecember 2020March 2025Abandon5130NoNo
17036671INTEGRATED HEALTHCARE METHODS AND SYSTEMSSeptember 2020December 2024Allow5040YesNo
16913940SENIOR LIVING CARE COORDINATION PLATFORMSJune 2020December 2025Abandon6080YesNo
16956185Portable Medical MemoryJune 2020October 2025Allow6060YesYes
16856865DIGITAL QUALIMETRIC BIOMARKERS FOR COGNITION AND MOVEMENT DISEASES OR DISORDERSApril 2020September 2024Allow5340YesNo
16812209ANALYSIS AND PRESENTATION OF AGGREGATED PATIENT AND DEVICE DATA WITHIN A SYSTEM THAT INCLUDES A MEDICAL DEVICEMarch 2020December 2024Allow5760YesNo
16619329PARAMETER VALUE ESTIMATION IN COAGULATION SYSTEMDecember 2019January 2026Abandon6060YesNo
16589374Identification of Clinical Inference RulesOctober 2019August 2025Abandon6020NoYes
16559465GENETIC VARIANT DETECTION BASED ON MERGED AND UNMERGED READSSeptember 2019May 2025Abandon6030NoNo
16294702GRAPHICAL DISPLAY OF DOSE RATE INFORMATION FOR RADIATION TREATMENT PLANNINGMarch 2019January 2026Allow6060YesYes
16292877SYSTEM AND METHOD FOR REVIEW OF AUTOMATED CLINICAL DOCUMENTATIONMarch 2019August 2025Abandon6040YesYes
16289450SYSTEMS AND METHODS FOR DETERMINING PATIENT HOSPITALIZATION RISK AND TREATING PATIENTSFebruary 2019January 2026Allow6080YesNo
16306704MEDICAL IMAGE WORKFLOW SYSTEM AND METHODDecember 2018September 2021Abandon3340NoYes
16103414MANAGING PROVIDER ROLES IN MEDICAL CAREAugust 2018July 2025Abandon6060YesYes
15794435BOTTLE CAP WITH ELECTRONIC EMBEDDED CURVED DISPLAYOctober 2017December 2024Allow6070YesYes
15355472SYSTEMS AND METHODS FOR GENERATING MEDICAL DIAGNOSISNovember 2016January 2025Abandon6050NoYes
15352488SYSTEMS AND METHODS FOR MEDICAL INSTRUMENT PATIENT MEASUREMENTSNovember 2016May 2023Abandon6070YesYes
15347146System for Collecting Medical Data Using Proxy InputsNovember 2016February 2025Abandon6070YesYes
15169689CONTEXT AND LOCATION SPECIFIC REAL TIME CARE MANAGEMENT SYSTEMMay 2016August 2025Abandon60100YesNo
15006274Medicine ingestion state management method, medicine and medicine ingestion state management deviceJanuary 2016September 2019Allow4420YesNo
14900448MULTIDIMENSIONAL TIME SERIES ENTRAINMENT SYSTEM, METHOD AND COMPUTER READABLE MEDIUMDecember 2015August 2025Abandon60130NoNo
14899764ECG FEATURES FOR TYPE AHEAD EDITING AND AUTOMATIC UPDATE FOR REPORT INTERPRETATIONDecember 2015April 2025Allow6080YesYes
13025617EXTENDED WEB ENABLED BUSINESS TO BUSINESS COMPUTER SYSTEM FOR RENTAL VEHICLE SERVICESFebruary 2011November 2012Allow2110NoNo
13025546METHOD AND SYSTEM FOR MANAGING RENTAL VEHICLE RESERVATIONS WITH USER AUTHORIZATION LIMITSFebruary 2011June 2012Allow1600NoNo
12964565HEALTH-CARE E-COMMERCE SYSTEMS AND METHODSDecember 2010January 2019Allow6080YesNo
12466684METHODS AND SYSTEMS FOR INTEGRATED HEALTH SYSTEMSMay 2009December 2012Allow4320YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COLEMAN, CHARLES P..

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
8
(88.9%)
Examiner Reversed
1
(11.1%)
Reversal Percentile
24.2%
Lower than average

What This Means

With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
2
(12.5%)
Not Allowed After Appeal Filing
14
(87.5%)
Filing Benefit Percentile
15.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner COLEMAN, CHARLES P. - Prosecution Strategy Guide

Executive Summary

Examiner COLEMAN, CHARLES P. works in Art Unit 3683 and has examined 33 patent applications in our dataset. With an allowance rate of 42.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.

Allowance Patterns

Examiner COLEMAN, CHARLES P.'s allowance rate of 42.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by COLEMAN, CHARLES P. receive 4.94 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by COLEMAN, CHARLES P. is 10000 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +36.4% benefit to allowance rate for applications examined by COLEMAN, CHARLES P.. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 5.7% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 13.9% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 45% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 35.7% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 20.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.